|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Taichman RS, Loberg RD, Mehra R and Pienta
KJ: The evolving biology and treatment of prostate cancer. J Clin
Invest. 117:2351–2361. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wenzel M, Garcia CC, Hoeh B, Jorias C,
Humke C, Koll F, Tselis N, Rödel C, Graefen M, Tilki D, et al:
Real-world evidence of outcomes of oligometastatic
hormone-sensitive prostate cancer patients treated with
metastasis-directed therapy. Prostate. 83:1365–1372. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rogowski P, Trapp C, von Bestenbostel R,
Schmidt-Hegemann NS, Shi R, Ilhan H, Kretschmer A, Stief C,
Ganswindt U, Belka C and Li M: Outcomes of metastasis-directed
therapy of bone oligometastatic prostate cancer. Radiat Oncol.
16:1252021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bubendorf L, Schöpfer A, Wagner U, Sauter
G, Moch H, Willi N, Gasser TC and Mihatsch MJ: Metastatic patterns
of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol.
31:578–583. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Berruti A, Dogliotti L, Bitossi R, Fasolis
G, Gorzegno G, Bellina M, Torta M, Porpiglia F, Fontana D and
Angeli A: Incidence of skeletal complications in patients with bone
metastatic prostate cancer and hormone refractory disease:
Predictive role of bone resorption and formation markers evaluated
at baseline. J Urol. 164:1248–1253. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sartor O and de Bono JS: Metastatic
prostate cancer. N Engl J Med. 378:645–657. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Uhr JW and Pantel K: Controversies in
clinical cancer dormancy. Proc Natl Acad Sci USA. 108:12396–12400.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ruppender NS, Morrissey C, Lange PH and
Vessella RL: Dormancy in solid tumors: Implications for prostate
cancer. Cancer Metastasis Rev. 32:501–509. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aguirre-Ghiso JA: Models, mechanisms and
clinical evidence for cancer dormancy. Nat Rev Cancer. 7:834–846.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Phan TG and Croucher PI: The dormant
cancer cell life cycle. Nat Rev Cancer. 20:398–411. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Aguirre-Ghiso JA, Estrada Y, Liu D and
Ossowski L: ERK(MAPK) activity as a determinant of tumor growth and
dormancy; regulation by p38(SAPK). Cancer Res. 63:1684–1695.
2003.PubMed/NCBI
|
|
13
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang W and Liu HT: MAPK signal pathways
in the regulation of cell proliferation in mammalian cells. Cell
Res. 12:9–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bragado P, Estrada Y, Parikh F, Krause S,
Capobianco C, Farina HG, Schewe DM and Aguirre-Ghiso JA: TGF-β2
dictates disseminated tumour cell fate in target organs through
TGF-beta-RIII and p38α/β signalling. Nat Cell Biol. 15:1351–1361.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Prunier C, Baker D, Ten Dijke P and Ritsma
L: TGF-β family signaling pathways in cellular dormancy. Trends
Cancer. 5:66–78. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sosa MS, Avivar-Valderas A, Bragado P, Wen
HC and Aguirre-Ghiso JA: ERK1/2 and p38α/β signaling in tumor cell
quiescence: Opportunities to control dormant residual disease. Clin
Cancer Res. 17:5850–5857. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yumoto K, Eber MR, Wang J, Cackowski FC,
Decker AM, Lee E, Nobre AR, Aguirre-Ghiso JA, Jung Y and Taichman
RS: Axl is required for TGF-β2-induced dormancy of prostate cancer
cells in the bone marrow. Sci Rep. 6:365202016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kobayashi A, Okuda H, Xing F, Pandey PR,
Watabe M, Hirota S, Pai SK, Liu W, Fukuda K, Chambers C, et al:
Bone morphogenetic protein 7 in dormancy and metastasis of prostate
cancer stem-like cells in bone. J Exp Med. 208:2641–2655. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Le Page-Degivry MT, Bidard JN, Rouvier E,
Bulard C and Lazdunski M: Presence of abscisic acid, a
phytohormone, in the mammalian brain. Proc Natl Acad Sci USA.
83:1155–118. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bruzzone S, Ameri P, Briatore L, Mannino
E, Basile G, Andraghetti G, Grozio A, Magnone M, Guida L, Scarfì S,
et al: The plant hormone abscisic acid increases in human plasma
after hyperglycemia and stimulates glucose consumption by
adipocytes and myoblasts. FASEB J. 26:1251–1260. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bruzzone S, Bodrato N, Usai C, Guida L,
Moreschi I, Nano R, Antonioli B, Fruscione F, Magnone M, Scarfì S,
et al: Abscisic acid is an endogenous stimulator of insulin release
from human pancreatic islets with cyclic ADP ribose as second
messenger. J Biol Chem. 283:32188–32197. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bruzzone S, Basile G, Mannino E, Sturla L,
Magnone M, Grozio A, Salis A, Fresia C, Vigliarolo T, Guida L, et
al: Autocrine abscisic acid mediates the UV-B-induced inflammatory
response in human granulocytes and keratinocytes. J Cell Physiol.
227:2502–2510. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bruzzone S, Moreschi I, Usai C, Guida L,
Damonte G, Salis A, Scarfì S, Millo E, De Flora A and Zocchi E:
Abscisic acid is an endogenous cytokine in human granulocytes with
cyclic ADP-ribose as second messenger. Proc Natl Acad Sci USA.
104:5759–5764. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Magnone M, Bruzzone S, Guida L, Damonte G,
Millo E, Scarfì S, Usai C, Sturla L, Palombo D, De Flora A and
Zocchi E: Abscisic acid released by human monocytes activates
monocytes and vascular smooth muscle cell responses involved in
atherogenesis. J Biol Chem. 284:17808–17818. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Magnone M, Sturla L, Jacchetti E, Scarfì
S, Bruzzone S, Usai C, Guida L, Salis A, Damonte G, De Flora A and
Zocchi E: Autocrine abscisic acid plays a key role in
quartz-induced macrophage activation. FASEB J. 26:1261–1271. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Scarfi S, Ferraris C, Fruscione F, Fresia
C, Guida L, Bruzzone S, Usai C, Parodi A, Millo E, Salis A, et al:
Cyclic ADP-ribose-mediated expansion and stimulation of human
mesenchymal stem cells by the plant hormone abscisic acid. Stem
Cells. 26:2855–2864. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li HH, Hao RL, Wu SS, Guo PC, Chen CJ, Pan
LP and Ni H: Occurrence, function and potential medicinal
applications of the phytohormone abscisic acid in animals and
humans. Biochem Pharmacol. 82:701–712. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sakthivel P, Sharma N, Klahn P, Gereke M
and Bruder D: Abscisic Acid: A phytohormone and mammalian cytokine
as novel pharmacon with potential for future development into
clinical applications. Curr Med Chem. 23:1549–1570. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fresia C, Vigliarolo T, Guida L, Booz V,
Bruzzone S, Sturla L, Di Bona M, Pesce M, Usai C, De Flora A and
Zocchi E: G-protein coupling and nuclear translocation of the human
abscisic acid receptor LANCL2. Sci Rep. 6:266582016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bassaganya-Riera J, Guri AJ, Lu P, Climent
M, Carbo A, Sobral BW, Horne WT, Lewis SN, Bevan DR and Hontecillas
R: Abscisic acid regulates inflammation via ligand-binding
domain-independent activation of peroxisome proliferator-activated
receptor gamma. J Biol Chem. 286:2504–2516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Leber A, Hontecillas R, Zoccoli-Rodriguez
V and Bassaganya-Riera J: Activation of LANCL2 by BT-11 Ameliorates
IBD by supporting regulatory T cell stability through
immunometabolic mechanisms. Inflamm Bowel Dis. 24:1978–1991. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Koeffler HP: Peroxisome
proliferator-activated receptor gamma and cancers. Clin Cancer Res.
9:1–9. 2003.PubMed/NCBI
|
|
34
|
Hisatake JI, Ikezoe T, Carey M, Holden S,
Tomoyasu S and Koeffler HP: Down-Regulation of prostate-specific
antigen expression by ligands for peroxisome proliferator-activated
receptor gamma in human prostate cancer. Cancer Res. 60:5494–5498.
2000.PubMed/NCBI
|
|
35
|
Sikka S, Chen L, Sethi G and Kumar AP:
Targeting PPARγ signaling cascade for the prevention and treatment
of prostate cancer. PPAR Res. 2012:9680402012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fizazi K and Navone NM: Preclinical models
of prostate cancer. Bull Cancer. 92:129–141. 2005.(In French).
PubMed/NCBI
|
|
37
|
Rosol TJ, Tannehill-Gregg SH, LeRoy BE,
Mandl S and Contag CH: Animal models of bone metastasis. Cancer. 97
(Suppl 3):S748–S57. 2003. View Article : Google Scholar
|
|
38
|
Chung LW, Kao C, Sikes RA and Zhau HE:
Human prostate cancer progression models and therapeutic
intervention. Hinyokika Kiyo. 43:815–820. 1997.PubMed/NCBI
|
|
39
|
Wang Y, Herroon MK, Zielske SP, Ellis L,
Podgorski I, Taichman RS and Cackowski FC: Use of FVB Myc-CaP cells
as an immune competent, androgen receptor positive, mouse model of
prostate cancer bone metastasis. J Bone Oncol. 30:1003862021.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Westbrook TF, Martin ES, Schlabach MR,
Leng Y, Liang AC, Feng B, Zhao JJ, Roberts TM, Mandel G, Hannon GJ,
et al: A genetic screen for candidate tumor suppressors identifies
REST. Cell. 121:837–848. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lin L, Chamberlain L, Pak ML, Nagarajan A,
Gupta R, Zhu LJ, Wright CM, Fong KM, Wajapeyee N and Green MR: A
large-scale RNAi-based mouse tumorigenesis screen identifies new
lung cancer tumor suppressors that repress FGFR signaling. Cancer
Discov. 4:1168–1181. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Oktem G, Bilir A, Uslu R, Inan SV, Demiray
SB, Atmaca H, Ayla S, Sercan O and Uysal A: Expression profiling of
stem cell signaling alters with spheroid formation in
CD133high/CD44high prostate cancer stem cells. Oncol Lett.
7:2103–2109. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jung Y, Cackowski FC, Yumoto K, Decker AM,
Wang Y, Hotchkin M, Lee E, Buttitta L and Taichman RS: Abscisic
acid regulates dormancy of prostate cancer disseminated tumor cells
in the bone marrow. Neoplasia. 23:102–111. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sharma S, Xing F, Liu Y, Wu K, Said N,
Pochampally R, Shiozawa Y, Lin HK, Balaji KC and Watabe K: Secreted
protein acidic and rich in cysteine (SPARC) mediates metastatic
dormancy of prostate cancer in bone. J Biol Chem. 291:19351–19363.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rebello RJ, Oing C, Knudsen KE, Loeb S,
Johnson DC, Reiter RE, Gillessen S, Van der Kwast T and Bristow RG:
Prostate cancer. Nat Rev Dis Primers. 7:92021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Roudier MP, Corey E, True LD, Hiagno CS,
Ott SM and Vessell RL: Histological, immunophenotypic and
histomorphometric characterization of prostate cancer bone
metastases. Cancer Treat Res. 118:311–339. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mehra R, Kumar-Sinha C, Shankar S, Lonigro
RJ, Jing X, Philips NE, Siddiqui J, Han B, Cao X, Smith DC, et al:
Characterization of bone metastases from rapid autopsies of
prostate cancer patients. Clin Cancer Res. 17:3924–3932. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Viale PH: The American Cancer Society's
facts & figures: 2020 edition. J Adv Pract Oncol. 11:135–136.
2020.PubMed/NCBI
|
|
50
|
Ku SY, Gleave ME and Beltran H: Towards
precision oncology in advanced prostate cancer. Nat Rev Urol.
16:645–654. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Patel VG and Oh WK: The evolving landscape
of immunotherapy in advanced prostate cancer. Immunotherapy.
11:903–912. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Watson PA, Arora VK and Sawyers CL:
Emerging mechanisms of resistance to androgen receptor inhibitors
in prostate cancer. Nat Rev Cancer. 15:701–711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Takezawa D, Komatsu K and Sakata Y: ABA in
bryophytes: How a universal growth regulator in life became a plant
hormone? J Plant Res. 124:437–453. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lievens L, Pollier J, Goossens A, Beyaert
R and Staal J: Abscisic acid as pathogen effector and immune
regulator. Front Plant Sci. 8:5872017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sano N and Marion-Poll A: ABA metabolism
and homeostasis in seed dormancy and germination. Int J Mol Sci.
22:50692021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chaqour J, Lee S, Ravichandra A and
Chaqour B: Abscisic acid-an anti-angiogenic phytohormone that
modulates the phenotypical plasticity of endothelial cells and
macrophages. J Cell Sci. 131:jcs2104922018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Baliño P, Gómez-Cadenas A, López-Malo D,
Romero FJ and Muriach M: Is there a role for abscisic acid, a
proven anti-inflammatory agent, in the treatment of ischemic
retinopathies? Antioxidants (Basel). 8:1042019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sturla L, Fresia C, Guida L, Bruzzone S,
Scarfì S, Usai C, Fruscione F, Magnone M, Millo E, Basile G, et al:
LANCL2 is necessary for abscisic acid binding and signaling in
human granulocytes and in rat insulinoma cells. J Biol Chem.
284:28045–28057. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Cao LQ, Shao ZL, Liang HH, Zhang DW, Yang
XW, Jiang XF and Xue P: Activation of peroxisome
proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell
growth via downregulation of SEPT2 expression. Cancer Lett.
359:127–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Bolden A, Bernard L, Jones D, Akinyeke T
and Stewart LV: The PPAR gamma agonist troglitazone regulates Erk
1/2 phosphorylation via a PPARγ-Independent, MEK-dependent pathway
in human prostate cancer cells. PPAR Res. 2012:9290522012.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Cho SJ, Kook MC, Lee JH, Shin JY, Park J,
Bae YK, Choi IJ, Ryu KW and Kim YW: Peroxisome
proliferator-activated receptor γ upregulates galectin-9 and
predicts prognosis in intestinal-type gastric cancer. Int J Cancer.
136:810–820. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Grommes C, Landreth GE and Heneka MT:
Antineoplastic effects of peroxisome proliferator-activated
receptor gamma agonists. Lancet Oncol. 5:419–429. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ogino S, Shima K, Baba Y, Nosho K, Irahara
N, Kure S, Chen L, Toyoda S, Kirkner GJ, Wang YL, et al: Colorectal
cancer expression of peroxisome proliferator-activated receptor
gamma (PPARG, PPARgamma) is associated with good prognosis.
Gastroenterology. 136:1242–1250. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wang C, Fu M, D'Amico M, Albanese C, Zhou
JN, Brownlee M, Lisanti MP, Chatterjee VK, Lazar MA and Pestell RG:
Inhibition of cellular proliferation through IkappaB
kinase-independent and peroxisome proliferator-activated receptor
gamma-dependent repression of cyclin D1. Mol Cell Biol.
21:3057–3070. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Elnemr A, Ohta T, Iwata K, Ninomia I,
Fushida S, Nishimura G, Kitagawa H, Kayahara M, Yamamoto M, Terada
T and Miwa K: PPARgamma ligand (thiazolidinedione) induces growth
arrest and differentiation markers of human pancreatic cancer
cells. Int J Oncol. 17:1157–1164. 2000.PubMed/NCBI
|
|
66
|
Itami A, Watanabe G, Shimada Y, Hashimoto
Y, Kawamura J, Kato M, Hosotani R and Imamura M: Ligands for
peroxisome proliferator-activated receptor gamma inhibit growth of
pancreatic cancers both in vitro and in vivo. Int J Cancer.
94:370–376. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Jabbar ZR and Sahib HB: The effects of
abscisic acid on angiogenesis in both ex vivo and in vivo assays.
Asian Pac J Cancer Prev. 23:4193–4203. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhao HF, Zhou XM, Wang J, Chen FF, Wu CP,
Diao PY, Cai LR, Chen L, Xu YW, Liu J, et al: Identification of
prognostic values defined by copy number variation, mRNA and
protein expression of LANCL2 and EGFR in glioblastoma patients. J
Transl Med. 19:3722021. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yousefnia S, Momenzadeh S, Seyed Forootan
F, Ghaedi K and Nasr Esfahani MH: The influence of peroxisome
proliferator-activated receptor γ (PPARγ) ligands on cancer cell
tumorigenicity. Gene. 649:14–22. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Spinelli S, Begani G, Guida L, Magnone M,
Galante D, D'Arrigo C, Scotti C, Iamele L, De Jonge H, Zocchi E and
Sturla L: LANCL1 binds abscisic acid and stimulates glucose
transport and mitochondrial respiration in muscle cells via the
AMPK/PGC-1α/Sirt1 pathway. Mol Metab. 53:1012632021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Biagioni B, Tomei L, Valleriani C,
Liccioli G, Barni S, Sarti L, Citera F, Giovannini M and Mori F:
Allergy to Gibberellin-Regulated Proteins (Peamaclein) in Children.
Int Arch Allergy Immunol. 182:1194–1199. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Nakagawa M, Hanada M, Inomata N and Amano
H: A case of a gibberellin-regulated protein-positive patient
allergic to various fruits. Eur J Dermatol. 31:88–90. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Inuo C, Okazaki F, Shiraki R, Tanaka Y,
Momma K, Kondo Y and Narita H: Generalized allergic reaction in
response to exercise due to strawberry gibberellin-regulated
protein: a case report. Allergy Asthma Clin Immunol. 18:492022.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Mo J, Kang M, Ye JX, Chen JB, Zhang HB and
Qing C: Gibberellin derivative GA-13315 sensitizes
multidrug-resistant cancer cells by antagonizing ABCB1 while
agonizes ABCC1. Cancer Chemother Pharmacol. 78:51–61. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Egbewande FA, Sadowski MC, Levrier C,
Tousignant KD, White JM, Coster MJ, Nelson CC and Davis RA:
Identification of gibberellic acid derivatives that deregulate
cholesterol metabolism in prostate cancer cells. J Nat Prod.
81:838–845. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Mukherjee A, Gaurav AK, Singh S, Yadav S,
Bhowmick S, Abeysinghe S and Verma JP: The bioactive potential of
phytohormones: A review. Biotechnol Rep (Amst). 35:e007482022.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Shuai HW, Meng YJ, Luo XF, Chen F, Qi Y,
Yang WY and Shu K: The roles of auxin in seed dormancy and
germination. Yi Chuan. 38:314–322. 2016.PubMed/NCBI
|
|
78
|
Sosa MS, Parikh F, Maia AG, Estrada Y,
Bosch A, Bragado P, Ekpin E, George A, Zheng Y, Lam HM, et al:
NR2F1 controls tumour cell dormancy via SOX9- and RARbeta-driven
quiescence programmes. Nat Commun. 6:61702015. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Chambard JC, Lefloch R, Pouysségur J and
Lenormand P: ERK implication in cell cycle regulation. Biochim
Biophys Acta. 1773:1299–1310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Yu C, Shiozawa Y, Taichman RS, McCauley
LK, Pienta K and Keller E: Prostate cancer and parasitism of the
bone hematopoietic stem cell niche. Crit Rev Eukaryot Gene Expr.
22:131–148. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Morrissey C, Vessella RL, Lange PH and Lam
HM: The biology and clinical implications of prostate cancer
dormancy and metastasis. J Mol Med (Berl). 94:259–265. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Cackowski FC and Taichman RS: Minimal
residual disease in prostate cancer. Adv Exp Med Biol. 1100:47–53.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Shiozawa Y, Pedersen EA, Patel LR, Ziegler
AM, Havens AM, Jung Y, Wang J, Zalucha S, Loberg RD, Pienta KJ and
Taichman RS: GAS6/AXL axis regulates prostate cancer invasion,
proliferation, and survival in the bone marrow niche. Neoplasia.
12:116–127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Jung Y, Shiozawa Y, Wang J, McGregor N,
Dai J, Park SI, Berry JE, Havens AM, Joseph J, Kim JK, et al:
Prevalence of prostate cancer metastases after intravenous
inoculation provides clues into the molecular basis of dormancy in
the bone marrow microenvironment. Neoplasia. 14:429–439. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Jung Y, Decker AM, Wang J, Lee E, Kana LA,
Yumoto K, Cackowski FC, Rhee J, Carmeliet P, Buttitta L, et al:
Endogenous GAS6 and Mer receptor signaling regulate prostate cancer
stem cells in bone marrow. Oncotarget. 7:25698–25711. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Cackowski FC and Taichman RS: Parallels
between hematopoietic stem cell and prostate cancer disseminated
tumor cell regulation. Bone. 119:82–86. 2019. View Article : Google Scholar : PubMed/NCBI
|
